A Randomized Phase II Study of DaRatumumab, Ixazomib, and Dexamethasone vs Daratumumab, Bortezomib (VElcade) and Dexamethasone Followed by Daratumumab-Ixazomib-Dexamethasone in Newly Diagnosed Multiple Myeloma (DeRIVE Study)
Latest Information Update: 25 Jun 2024
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DeRIVE
Most Recent Events
- 18 Jun 2024 Planned End Date changed from 31 Jul 2025 to 31 Jul 2026.
- 18 Jun 2024 Planned primary completion date changed from 31 Jul 2024 to 31 Jul 2025.
- 12 Dec 2023 Results (n=48) assessing safety and efficacy of of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition